PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.

about

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.

Item

http://www.wikidata.org/entity/Q42371630

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

PD-L1 expression indicates fav ...... ients treated with pemetrexed.

@en

PD-L1 expression indicates fav ...... ients treated with pemetrexed.

@nl

type

Item

label

PD-L1 expression indicates fav ...... ients treated with pemetrexed.

@en

PD-L1 expression indicates fav ...... ients treated with pemetrexed.

@nl

prefLabel

PD-L1 expression indicates fav ...... ients treated with pemetrexed.

@en

PD-L1 expression indicates fav ...... ients treated with pemetrexed.

@nl

P1476

PD-L1 expression indicates fav ...... tients treated with pemetrexed

@en

P2093

Guohua Lu

http://www.w3.org/2001/XMLSchema#string

Jianya Zhou

http://www.w3.org/2001/XMLSchema#string

Jianying Zhou

http://www.w3.org/2001/XMLSchema#string

Liming Xu

http://www.w3.org/2001/XMLSchema#string

Pei Zhang

http://www.w3.org/2001/XMLSchema#string

Qiqi Gao

http://www.w3.org/2001/XMLSchema#string

Rong Liu

http://www.w3.org/2001/XMLSchema#string

Yihong Shen

http://www.w3.org/2001/XMLSchema#string

Yinan Yao

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Cancer statistics, 2016

Lung cancer

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Nivolumab in previously untreated melanoma without BRAF mutation

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

P304

66293-66304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19973

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zhang Bao

P577

2017-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29029512

http://www.w3.org/2001/XMLSchema#string

P932

5630412

http://www.w3.org/2001/XMLSchema#string